Khiron Life Sciences Corp. — Capital/Financing Update 2020

Nov 23, 2020

==> picture [612 x 50] intentionally omitted <==

==> picture [612 x 51] intentionally omitted <==

November 23, 2020

FILED BY SEDAR

British Columbia Securities Commission Alberta Securities Commission Saskatchewan Financial and Consumer Affairs Authority The Manitoba Securities Commission Ontario Securities Commission Financial and Consumer Services Commission, New Brunswick Nova Scotia Securities Commission Office of the Superintendent of Securities, Prince Edward Island Office of the Superintendent of Securities, Government of Newfoundland and Labrador

Dear Sirs/Mesdames:

RE: Khiron Life Sciences Corp. (the “Corporation”) Final Short Form Prospectus dated November 23, 2020 (the “Prospectus”)

We refer to the Prospectus of the Corporation relating to an offering of units.

We, as counsel to the underwriters, hereby consent to the use of and reference to our firm opinion under the heading “Eligibility for Investment” and to the reference to our firm name on page iii of the Prospectus and under the heading “Legal Matters”.

We confirm that we have read the Prospectus and that we have no reason to believe that there are any misrepresentations in the information contained therein that is derived from our opinion referred to above or that is within our knowledge as a result of the services we performed in connection with such opinion.

Yours truly,

“CASSELS BROCK & BLACKWELL LLP”

==> picture [612 x 55] intentionally omitted <==

==> picture [612 x 55] intentionally omitted <==